Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors

Loading news article.

Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors | WAPE

Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors

Article summary

Related companies

Comments —